The World Health Organisation issues new GLP-1 guidelines, recognises their LONG TERM efficacy in treating obesity and improving metabolic and other outcomes, calls for fair access to GLP-1s. Worth showing your doctor if you want to stay on them and are being told to titrate down and stop using.
rest of post lifted directly from WHO release 👇
- GLP-1 therapies may be used by adults, but excluding pregnant women, for the long-term treatment of obesity. While the efficacy of these therapies in treating obesity and improving metabolic and other outcomes was evident, the recommendation is conditional due to limited data on their long-term efficacy and safety, maintenance and discontinuation, their current costs, inadequate health-system preparedness, and potential equity implications.
- Intensive behavioural interventions, including structured interventions involving healthy diet and physical activity, may be offered to adults living with obesity prescribed GLP-1 therapies. This is based on low-certainty evidence suggesting it may enhance treatment outcomes.
Medication alone won’t reverse the obesity challenge
While GLP-1 therapies represent the first efficacious treatment option for adults with obesity, the WHO guideline emphasizes that medicines alone will not solve the problem. Obesity is not only an individual concern but also a societal challenge that requires multisectoral action. Addressing obesity requires a fundamental reorientation of current approaches to a comprehensive strategy built with three pillars:
- Creating healthier environments through robust population-level policies to promote health and prevent obesity;
- Protecting individuals at high risk of developing obesity and related comorbidities through targeted screening and structured early interventions; and
- Ensuring access to lifelong, person-centred care.
Implementation considerations
The guideline emphasizes the importance of fair access to GLP-1 therapies and preparing health systems for use of these medicines. Without deliberate policies, access to these therapies could exacerbate existing health disparities. WHO calls for urgent action on manufacturing, affordability, and system readiness to meet global needs.
Even with rapid expansion in production, GLP-1 therapies are projected to reach fewer than 10% of those who could benefit by 2030. The guideline calls on the global community to consider strategies to expand access, such as pooled procurement, tiered pricing, and voluntary licensing among others.